Treatments for gastrointestinal disorders

Inventors

Kessler, Marco • Fretzen, Angelika • Zhao, Hong • Solinga, Robert • Volchenok, Vladimir

Assignees

Ironwood Pharmaceuticals Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-9708371-B2

Patent

Publication Date

2017-07-18

Expiration Date


Abstract

The present invention features peptides, compositions, and related methods for treating gastrointestinal disorders and conditions, including but not limited to, irritable bowel syndrome (IBS), gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia, visceral pain, gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), disorders and conditions associated with constipation, and other conditions and disorders are described herein, using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.

Core Innovation

The invention relates to GC-C-targeting linaclotide-based peptides for activating the guanylate cyclase C receptor. The peptide comprises a modified amino-acid structure derived from linaclotide, including a Cys1-α-Ketone peptide comprising the amino acid structure of SEQ ID NO:2, with emphasis on activation and binding to GC-C and downstream signaling involving cGMP.

Pharmaceutical compositions include linaclotide and the Cys1-α-Ketone peptide at low relative weight percentages versus linaclotide, including compositions that consist essentially of the active peptide(s). Embodiments include linaclotide trisulfide products formed by adding an additional sulfur atom to linaclotide cysteinyl sulfurs, with corresponding low composition levels, and variants with altered Cys crosslinks.

Methods are described for treating gastrointestinal disorders by administering linaclotide together with the Cys1-α-Ketone peptide or linaclotide trisulfide. The disclosed disorders include IBS, constipation, functional gastrointestinal disorder, gastroesophageal reflux disease, functional heartburn, dyspepsia, visceral pain, gastroparesis, chronic/colonic pseudo-obstruction, Crohn’s disease, ulcerative colitis, inflammatory bowel disease, and duodenogastric reflux.

Claims Coverage

The claims cover a guanylate cyclase C receptor activating peptide defined by a specified amino-acid structure, and extend to pharmaceutical compositions that combine the peptide with linaclotide at low relative peptide-to-linaclotide weight percentages, with formulation and therapeutic-use limitations. One inventive feature is identified across the independent claim scope.

Guanylate cyclase C activating peptide structure

A peptide or a pharmaceutically acceptable salt thereof, wherein the peptide comprises the amino acid structure of the depicted structure and activates the guanylate cyclase C receptor.

Peptide specified by SEQ ID NO:2

The peptide, or a pharmaceutically acceptable salt of the peptide, is specified as SEQ ID NO:2.

Low peptide-to-linaclotide relative weight in a pharmaceutical composition

A pharmaceutical composition further includes linaclotide, where the peptide or a pharmaceutically acceptable salt thereof is present at 0.01–5% by weight relative to linaclotide.

Selected gastrointestinal disorders for treatment

The gastrointestinal disorder is selected from IBS, constipation, functional gastrointestinal disorders, gastroesophageal reflux disease, functional heartburn, dyspepsia, visceral pain, gastroparesis, chronic and colonic pseudo-obstruction, Crohn’s disease, ulcerative colitis, inflammatory bowel disease, and duodenogastric reflux.

Across the independent claim scope, the inventive concept is a GC-C-activating linaclotide-based peptide, or salt, comprising a specified amino-acid structure. Dependent claim coverage further specifies SEQ ID NO-related forms, pharmaceutical composition constraints, and therapeutic use for selected gastrointestinal disorders.

Stated Advantages

Activates the guanylate cyclase C receptor.

Provides a mechanism associated with increased cGMP leading to chloride or bicarbonate secretion and increased intestinal transit.

Documented Applications

Methods of treating gastrointestinal disorders by administering linaclotide together with the Cys1-α-Ketone peptide or linaclotide trisulfide, including IBS, constipation, functional gastrointestinal disorders, gastroesophageal reflux disease, functional heartburn, dyspepsia, visceral pain, gastroparesis, chronic/colonic pseudo-obstruction, Crohn’s disease, ulcerative colitis, inflammatory bowel disease, and duodenogastric reflux.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.